Niepubliczny Zaklad Opieki Zdrowotnej Salmed

Research site

Poland Ul. Waclawa Jawoszka 3, 21-010 Leczna, Poland

2 trials recruiting
Pneumococcal immunisation · Influenza · Meningococcal infection
Children and adolescents

About Specializations

Niepubliczny Zaklad Opieki Zdrowotnej Salmed in Leczna, Poland specialises in clinical trials of conditions such as Pneumococcal immunisation, Influenza, Meningococcal infection, Pneumococcal infection, and other specialisations. This site conducts important research.

Main research areas of the site

Bacterial Infections and Mycoses

At Niepubliczny Zaklad Opieki Zdrowotnej Salmed, the research team is dedicated to preventing meningococcal infection by evaluating new vaccine options for young children.

Development of a conjugate vaccine targeting serogroups A, C, W, and Y
Assessment of immunogenicity in infants and toddlers
Safety monitoring in healthy volunteers
Comparison of antibody responses to an established vaccine

The ongoing studies aim to demonstrate non‑inferior immune protection using geometric mean titers as a measure of response, while also confirming the safety profile of the investigational MenACYW conjugate vaccine in this pediatric population.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Ul. Waclawa Jawoszka 321-010 LecznaPoland

Open in maps ↗

Recruiting now: 2 trials
Conditions studied: 5

More sites in Leczna Poland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

6 clinical trials

Pneumococcal immunisation

Recruiting

Safety of PF-07872412 versus 20‑valent pneumococcal conjugate vaccine in healthy infants for prevention of pneumococcal disease

Registered drugNo placebo

Safety of PF-07872412 versus 20‑valent pneumococcal conjugate vaccine in healthy infants for prevention of pneumococcal disease

Registered drugNo placebo

Poland

Participants:0–17 years
Substances:PF-07831695
Sponsor:Pfizer Inc.

Contact Research Centre

Influenza

Recruiting

Study on Baloxavir Marboxil for Children with Influenza

Registered drugNo placebo

Study on Baloxavir Marboxil for Children with Influenza

Registered drugNo placebo

Poland

Participants:0–17 years
Substances:Baloxavir Marboxil
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Pneumococcal immunisation

Not yet recruiting

Safety and immune response of PF-07872412 compared with 20-valent pneumococcal conjugate vaccine for pneumococcal disease in healthy children and adolescents

Registered drugNo placebo

Safety and immune response of PF-07872412 compared with 20-valent pneumococcal conjugate vaccine for pneumococcal disease in healthy children and adolescents

Registered drugNo placebo

Poland

Participants:0–17 years
Substances:PF-07831695
Sponsor:Pfizer Inc.

Contact Research Centre

Pneumococcal infection

Not recruiting

Study on the Safety and Immune Response of PF-07831695 and a Drug Combination for Pneumococcal Infections in Healthy Toddlers Aged 12-15 Months

Registered drugNo placebo

Study on the Safety and Immune Response of PF-07831695 and a Drug Combination for Pneumococcal Infections in Healthy Toddlers Aged 12-15 Months

Registered drugNo placebo

Poland

Participants:0–17 years · Healthy volunteers
Substances:PF-07831695
Sponsor:Pfizer Inc.

Contact Research Centre

Meningococcal infection

Not recruiting

Study on the Safety and Immune Response of MenACYW Conjugate Vaccine Compared to a Drug Combination in Healthy Infants and Toddlers

Registered drugNo placebo

Study on the Safety and Immune Response of MenACYW Conjugate Vaccine Compared to a Drug Combination in Healthy Infants and Toddlers

Registered drugNo placebo

Poland

Participants:0–17 years · Healthy volunteers
Substances:N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid
Sponsor:Sanofi Pasteur

Contact Research Centre

Respiratory syncytial virus infection

Not recruiting

Study on the Safety and Effectiveness of MK-1654 for Preventing Respiratory Syncytial Virus (RSV) in Healthy Pre-Term and Full-Term Infants

Registered drug

Study on the Safety and Effectiveness of MK-1654 for Preventing Respiratory Syncytial Virus (RSV) in Healthy Pre-Term and Full-Term Infants

Registered drug

Poland

Participants:0–17 years · Healthy volunteers
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites